Back to Search
Start Over
One-year and longer dual antiplatelet therapy after an acute coronary syndrome: a Belgian position paper.
- Source :
-
Acta cardiologica [Acta Cardiol] 2017 Feb; Vol. 72 (1), pp. 19-27. - Publication Year :
- 2017
-
Abstract
- Acute coronary syndrome patients receive DAPT up to one year after their initial event. Exceptions to the guideline-recommended one-year rule, however, are not uncommon. The reasoning behind shorter treatments, such as unacceptable bleeding risk or urgent surgery, should be well documented in the patient's charts and discharge letter. Based on recent evidence, patients at high risk for repetitive events should continue on low-dose ticagrelor without a significant interruption at one year and indefinitely in the absence of excess bleeding risk. As there is currently no reimbursement, policy makers and insurers should be made aware of the continuing risk and unmet clinical need in this patient population. Nevertheless, many unsolved questions need to be answered, both through additional analyses from recent trials such as PEGASUS-TIMI 54 or DAPT, as well as new carefully designed clinical studies.
- Subjects :
- Drug Administration Schedule
Drug Therapy, Combination
Follow-Up Studies
Global Health
Hemorrhage epidemiology
Humans
Incidence
Platelet Aggregation Inhibitors adverse effects
Risk Factors
Time Factors
Acute Coronary Syndrome drug therapy
Consensus
Hemorrhage chemically induced
Platelet Aggregation Inhibitors administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 0001-5385
- Volume :
- 72
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Acta cardiologica
- Publication Type :
- Academic Journal
- Accession number :
- 28597739
- Full Text :
- https://doi.org/10.1080/00015385.2017.1281563